Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatology Other
    Zoledronic Acid Improves Bone Loss Associated With Adjuvant AI Therapy in Postmenopausal Breast Cancer Patients: Presented at SABCS - (DGDispatch)
    Ibandronate Offers Pain Relief With Renal Safety in Women With Breast Cancer, Metastatic Bone Disease: Presented at SABCS - (DGDispatch)
    Severe Joint Pain in Multiple Areas Associated With Increased Risk of Falls in Older Adults - (DGNews)
    Canakinumab Gives Faster, Greater Pain Relief in Refractory Gout Patients: Presented at ACR/ARHP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatology Other
    • Improving Patient Outcomes in Fibromyalgia Syndrome: A Clinical Update on Appropriate Diagnosis, Adequate Treatment, and Proper Management of Comorbid Conditions
    • Understanding the Potential Etiologies of Fibromyalgia
    • Treatment Options for Fibromyalgia: Where Do We Stand?
    • Identifying and Adequately Managing Comorbidity in Fibromyalgia
    • Emerging Safety Issues in Biologics 2009: Progressive Multifocal Leukoencephalopathy

      Webcasts/CME archive

       Recent cases - Rheumatology Other
        Primary Biliary Cirrhosis-Autoimmune Hepatitis Overlap Syndrome Concomitant with Systemic Sclerosis, Immune Thrombocytopenic Purpura
        Relapsing Macrophage Activating Syndrome In A 15-Year-Old Girl With Still's Disease: A Case Report
        Pigmented Villonodular Synovitis of the Knee in a Patient on Oral Anticoagulation Therapy: A Case Report
        Rectal Mucosal Prolapse Syndrome as an Unusual Gastrointestinal Manifestation of Sjogren's Syndrome: A Case Report
        HELLP Syndrome, Multiple Liver Infarctions, and Intrauterine Fetal Death in a Patient with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

        Cases archive
          




        my personal edition > rheumatology other > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Rilonacept Approved in the EU for Cryopyrin-Associated Periodic Syndromes

        TARRYTOWN, NY -- October 27, 2009 -- The interleukin-1 (IL-1) blocker rilonacept (Arcalyst) is now approved in the European Union for the treatment of cryopyrin-associated periodic syndromes (CAPS) with severe symptoms, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells syndrome (MWS), in adults and children over age 12 years.

        CAPS include a group of rare, inherited, auto-inflammatory conditions characterised by life-long, recurrent symptoms of rash, fever/chills, joint pain, eye redness/pain, and fatigue. Intermittent, disruptive exacerbations or flares can be triggered at any time by exposure to cooling temperatures, stress, exercise, or other unknown stimuli.

        Rilonacept is a targeted inhibitor of IL-1, the key driver of inflammation in CAPS. In the clinical development programme, patients treated with rilonacept reported a greater improvement in overall symptom scores than patients treated with placebo. These improvements were sustained over time with continued rilonacept treatment. Patients reported their symptoms using a validated daily diary instrument. These assessments represent a critical measure of effectiveness in a disease characterised by frequent, unpredictable symptom flares of variable severity and duration. Unlike other agents used in the treatment of CAPS, rilonacept is supported by patient-reported symptoms data using a validated assessment instrument.

        Rilonacept is a once-weekly injection which can be administered at home by the patient or their caregiver following appropriate training. The most commonly reported adverse reactions with rilonacept were injection-site reaction and upper respiratory tract infection. IL-1 blockade may interfere with immune response to infections and treatment should not be initiated in patients with active or chronic infections. Serious, life-threatening infections have been reported in patients taking rilonacept; rilonacept should be discontinued if a patient develops a serious infection.

        The authorisation for approval of rilonacept in the European Union under exceptional circumstances is permissible for products for which a company can demonstrate that comprehensive data cannot be provided, for example, because of the rarity of the condition. Each year, Regeneron will need to provide the European Medicines Agency (EMEA) with any new information that may become available for review.

        Rilonacept has not been studied in patients with neonatal-onset multisystem inflammatory disease (NOMID), 1 of the 3 conditions that make up CAPS.

        Approximately 1 in 1,000,000 people in the European Union have CAPS. CAPS are generally caused by autosomal-dominant mutations in the NLRP-3 (previously known as CIAS1) gene and resultant alterations in the protein cryopyrin, which it encodes. Cryopyrin, active in circulating, infection-fighting, white blood cells, controls the production of IL-1. As part of the body's infection-fighting defence system, IL-1 circulates throughout the body and can trigger inflammatory reactions when it binds to inflammatory cells. Researchers have found that alterations in the cryopyrin protein lead to over-production of IL-1, resulting in an inflammatory response and the symptoms of CAPS. Most, but not all, patients with CAPS have the NLRP-3 gene mutation.

        SOURCE: Regeneron Pharmaceuticals, Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send